• Mutation; HGNC; HGNC:7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Hemizygous (from parent cell line).
  

PubMed=25382610; DOI=10.1038/bcj.2014.74; PMCID=PMC5424099
Chitta K.S., Paulus A., Caulfield T.R., Akhtar S., Blake M.K.K., Ailawadhi S., Knight J., Heckman M.G., Pinkerton A.B., Chanan-Khan A.A.
Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenstroms macroglobulinemia.
Blood Cancer J. 4:e260.1-e260.10(2014)

PubMed=28548645; DOI=10.1038/bcj.2017.40; PMCID=PMC5518884
Paulus A., Akhtar S., Yousaf H.M., Manna A., Paulus S.M., Bashir Y., Caulfield T.R., Blake M.K.K., Chitta K.S., Wang X., Asmann Y., Hudec R., Springer W., Ailawadhi S., Chanan-Khan A.A.
Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.
Blood Cancer J. 7:e565.1-e565.11(2017)